Researchers have found a powerful combination of three immune-targeting drugs that may succeed where others fail. By blocking key immune “brakes” used by cancer cells to hide, this therapy helps the ...
Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting ...
The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with reassurance, ...
A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment — an advance that points the way toward a possible cure for a disease that affects 40 ...
INSTI, Tenofovir-Free Regimen DOR/ISL Gains FDA Approval for HIV This fixed-dose, 2-drug combination is a once-daily, ...
FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results